Skip to main content
. Author manuscript; available in PMC: 2017 Nov 17.
Published in final edited form as: Int J Radiat Oncol Biol Phys. 2014 Mar 25;89(2):322–329. doi: 10.1016/j.ijrobp.2014.02.022

Table 2.

First site of progression by treatment type

Factor Treatment, n (%)
p value
Erlotinib
(n=52)
Whole-brain radiation therapy
(n=25)
Stereotactic Radiosurgery
(n=14)
First site of progression 0.004
 Outside of the brain 21 (41) 19 (76) 4 (29)
 Brain or both at same time 30 (59) 6(24) 10 (71)